Vantictumab, formerly labeled as OMP18R5, represents a novel targeted agent designed with specifically block OPN molecule 18R5. Such therapy is being developed by Amgen for potential treatments in multiple bone https://bookmark-dofollow.com/story28081684/vantictumab-a-deep-dive-into-this-engineered-immune-agent